scholarly journals Reduction of Pulmonary Inflammation by pH Modifiers

2021 ◽  
Author(s):  
Wei-ping Zeng
Keyword(s):  
Pulmonary Inflammation ◽  
Inflammatory Cells ◽  
Lung Parenchyma ◽  
Pathological Feature ◽  
Mucus Hypersecretion ◽  
Adverse Side Effects ◽  
New Class ◽  
Asthma Model ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Abstract Pulmonary inflammation is a common pathological feature of a variety of diseases, of which successful therapy with currently available anti-inflammatory drugs is limited by resistance and adverse side effects. Using the ovalbumin-induced mouse allergic asthma model, the present study shows that treatments with pH modifiers, particularly simple acids such as acetate or hydrochloric acid, effectively depleted inflammatory cells in the lungs and blood as well as hyperplastic lung tissue cells while preserving the structure of the blood vessels and lung parenchyma. The acid treatments also suppressed mucus hypersecretion. These results demonstrated pH modifiers as a new class of broad-spectrum anti-inflammatory agents with anti-proliferation and mucus suppression activities.

scholarly journals Reduction of Pulmonary Inflammation by pH Modifiers

2022 ◽  
Author(s):  
Wei-ping Zeng
Keyword(s):  
Pulmonary Inflammation ◽  
Inflammatory Cells ◽  
Pathological Feature ◽  
Successful Therapy ◽  
Mucus Hypersecretion ◽  
Adverse Side Effects ◽  
New Class ◽  
Asthma Model ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Abstract Pulmonary inflammation is a common pathological feature of a variety of diseases, ofwhich successful therapy with currently available anti-inflammatory drugs is limited byresistance and adverse side effects. Using the ovalbumin-induced mouse allergic asthma model,the present study shows that treatments with pH modifiers, particularly simple acids such asacetate or hydrochloric acid, effectively depleted inflammatory cells in the lungs and blood aswell as hyperplastic lung tissue cells while preserving the structure of the blood vessels and lungparenchyma. The acid treatments also suppressed mucus hypersecretion. These resultsdemonstrated pH modifiers as a new class of broad-spectrum anti-inflammatory agents with antiproliferationand mucus suppression activities.

Towards developing new strategies to reduce the adverse side-effects of nonsteroidal anti-inflammatory drugs

2011 ◽  
Vol 16 (1) ◽  
pp. 25-29 ◽  
Author(s):  
Noritaka Kawada ◽  
Toshiki Moriyama ◽  
Harumi Kitamura ◽  
Ryohei Yamamoto ◽  
Yoshiyuki Furumatsu ◽  
...  
Keyword(s):  
Side Effects ◽  
Adverse Side Effects ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
New Strategies

scholarly journals Chemotherapeutic Properties of Phospho-Nonsteroidal Anti-Inflammatory Drugs, a New Class of Anticancer Compounds

2011 ◽  
Vol 71 (24) ◽  
pp. 7617-7627 ◽  
Author(s):  
Liqun Huang ◽  
Gerardo G. Mackenzie ◽  
Yu Sun ◽  
Nengtai Ouyang ◽  
Gang Xie ◽  
...  
Keyword(s):  
Anticancer Compounds ◽  
New Class ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

A new family of 2-hydroxy fatty acids as a new class of non-steroid anti-inflammatory drugs

2010 ◽  
Vol 163 ◽  
pp. S41 ◽  
Author(s):  
Daniel Horacio López ◽  
María Laura Martín ◽  
María Antonia Noguera-Salva ◽  
Silvia Terés ◽  
Gwendolyn Barceló Coblijn ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Hydroxy Fatty Acids ◽  
New Class ◽  
New Family ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Pleurotus eryngiiAmeliorates Lipopolysaccharide-Induced Lung Inflammation in Mice

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Junya Kawai ◽  
Tsugunobu Andoh ◽  
Kenji Ouchi ◽  
Satoshi Inatomi
Keyword(s):  
Lung Inflammation ◽  
Pulmonary Inflammation ◽  
Inflammatory Cells ◽  
Lavage Fluid ◽  
Beneficial Effects ◽  
Lps Challenge ◽  
Heat Treated ◽  
Cultivated Mushroom ◽  
Anti Inflammatory ◽  
Intranasal Instillation

Pleurotus eryngii(P. eryngii) is consumed as a fresh cultivated mushroom worldwide and demonstrated to have multiple beneficial effects. We investigated the anti-inflammatory effect ofP. eryngiiin mice with acute lung injury (ALI). Intranasal instillation of lipopolysaccharide (LPS) (10 μg/site/mouse) induced marked lung inflammation (increase in the number of inflammatory cells, protein leakage, and production of nitric oxide in bronchoalveolar lavage fluid) as well as histopathological damage in the lung, 6 h after treatment. Mice administered heat-treatedP. eryngii(0.3–1 g/kg, p.o. (HTPE)) 1 h before LPS challenge showed decreased pulmonary inflammation and ameliorated histopathological damage. These results suggest that HTPE has anti-inflammatory effects against ALI. Thus,P. eryngiiitself may also have anti-inflammatory effects and could be a beneficial food for the prevention of ALI induced by bacterial infection.

scholarly journals Anti-Inflammatory Drugs in the Treatment of Meconium Aspiration Syndrome

2011 ◽  
Vol 11 (Supplement-1) ◽  
pp. 15-23
Author(s):  
D. Mokra ◽  
J. Mokry ◽  
A. Calkovska
Keyword(s):  
Lung Parenchyma ◽  
Meconium Aspiration Syndrome ◽  
Experimental Models ◽  
Lung Edema ◽  
Meconium Aspiration ◽  
Pulmonary Vasoconstriction ◽  
Severe Impairment ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Inflammatory Changes

Anti-Inflammatory Drugs in the Treatment of Meconium Aspiration SyndromeMeconium aspiration syndrome (MAS) is a major cause of respiratory distress in both the term and post-term neonates. Obstruction of the airways, dysfunction of pulmonary surfactant, inflammation, lung edema, pulmonary vasoconstriction and bronchoconstriction participate in the pathogenesis of this disorder. Since the inflammatory changes associated with meconium aspiration cause a severe impairment of the lung parenchyma including surfactant and influence the reactivity of both vascular and airway smooth muscle, administration of anti-inflammatory drugs may be of benefit also in the management of MAS. This article reviews effects of various anti-inflammatory drugs used in experimental models of MAS as well as in the treatment of newborns with meconium aspiration.

scholarly journals The COX-2 pathway is essential during early stages of skeletal muscle regeneration

2004 ◽  
Vol 287 (2) ◽  
pp. C475-C483 ◽  
Author(s):  
Brenda A. Bondesen ◽  
Stephen T. Mills ◽  
Kristy M. Kegley ◽  
Grace K. Pavlath
Keyword(s):  
Skeletal Muscle ◽  
Muscle Regeneration ◽  
Inflammatory Cells ◽  
Skeletal Muscle Regeneration ◽  
Cellular Processes ◽  
Early Stages ◽  
Inflammatory Drugs ◽  
Cox 2 ◽  
Anti Inflammatory

Skeletal muscle regeneration comprises several overlapping cellular processes, including inflammation and myogenesis. Prostaglandins (PGs) may regulate muscle regeneration, because they modulate inflammation and are involved in various stages of myogenesis in vitro. PG synthesis is catalyzed by different isoforms of cyclooxygenase (COX), which are inhibited by nonsteroidal anti-inflammatory drugs. Although experiments employing nonsteroidal anti-inflammatory drugs have implicated PGs in tissue repair, how PGs regulate muscle regeneration remains unclear, and the potentially distinct roles of different COX isoforms have not been investigated. To address these questions, a localized freeze injury was induced in the tibialis anterior muscles of mice chronically treated with either a COX-1- or COX-2-selective inhibitor (SC-560 and SC-236, respectively), starting before injury. The size of regenerating myofibers was analyzed at time points up to 5 wk after injury and found to be decreased by SC-236 and in COX-2−/− muscles, but unaffected by SC-560. In contrast, SC-236 had no effect on myofiber growth when administered starting 7 days after injury. The attenuation of myofiber growth by SC-236 treatment and in COX-2−/− muscles is associated with decreases in the number of myoblasts and intramuscular inflammatory cells at early times after injury. Together, these data suggest that COX-2-dependent PG synthesis is required during early stages of muscle regeneration and thus raise caution about the use of COX-2-selective inhibitors in patients with muscle injury or disease.

scholarly journals The use of hyaluronic acid preparations for the treatment of osteoarthritis of the major joints

2021 ◽  
Vol 4 (2) ◽  
pp. 11-16
Author(s):  
O Kalashnikov ◽  
O Sulyma ◽  
T Osadchuk ◽  
V Zayets ◽  
T Nizalov ◽  
...  
Keyword(s):  
Side Effects ◽  
Adverse Side Effects ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
High Level ◽  
Time Of Administration ◽  
Inflammatory Effect ◽  
The Ideal

The authors of the article analyzed the experience of domestic and foreign experts in the effectiveness of the use of HA preparations in the treatment of osteoarthritis of major joints. Background  and  Objective. To analyze the literature sources in order to determine the effectiveness of the use of HA preparations in the treatment of osteoarthritis of major ligaments. Materials and methods. Articles in specialized scientific journals and collections, Internet resource.Results. The analysis of literature sources determined the important role of HA preparations in the supplying and functioning of the articular cartilage. Researchers are inclined to believe that the ideal HA preparation should be as close as possible to the physiological HA of the synovial fluid of the joint. The developed domestic drug Artro-Patch fully corresponds to these parameters. Conclusions. The use of modern injectable HA preparations is advisable at stages 1–3 of OA. Anti-inflammatory effect of HA preparations makes it possible to reduce the dose and time of administration of non-steroidal anti-inflammatory drugs and, as a consequence, reduce the risk of developing many adverse side effects of NSAIDs. The high level of safety of HA preparations, the absence of serious side effects during their long-term use determine their widespread use in the clinical practice of modern orthopedists.

scholarly journals The efficacy and safety of pinocembrin in a sheep model of bleomycin-induced pulmonary fibrosis

PLoS ONE ◽  
2021 ◽  
Vol 16 (12) ◽  
pp. e0260719
Author(s):  
Habtamu B. Derseh ◽  
Jason Q. D. Goodger ◽  
Jean-Pierre Y. Scheerlinck ◽  
Chrishan S. Samuel ◽  
Ian E. Woodrow ◽  
...  
Keyword(s):  
Animal Model ◽  
Pulmonary Fibrosis ◽  
Inflammatory Cells ◽  
Lung Parenchyma ◽  
Lung Compliance ◽  
Large Animal Model ◽  
Large Animal ◽  
Lung Pathology ◽  
Sheep Model ◽  
Anti Inflammatory

The primary flavonoid, pinocembrin, is thought to have a variety of medical uses which relate to its reported anti-oxidant, anti-inflammatory, anti-microbial and anti-cancer properties. Some studies have reported that this flavonoid has anti-fibrotic activities. In this study, we investigated whether pinocembrin would impede fibrosis, dampen inflammation and improve lung function in a large animal model of pulmonary fibrosis. Fibrosis was induced in two localized lung segments in each of the 10 sheep participating in the study. This was achieved via two infusions of bleomycin delivered bronchoscopically at a two-week interval. Another lung segment in the same sheep was left untreated, and was used as a healthy control. The animals were kept for a little over 5 weeks after the final infusion of bleomycin. Pinocembrin, isolated from Eucalyptus leaves, was administered to one of the two bleomycin damaged lung segments at a dose of 7 mg. This dose was given once-weekly over 4-weeks, starting one week after the final bleomycin infusion. Lung compliance (as a measure of stiffness) was significantly improved after four weekly administrations of pinocembrin to bleomycin-damaged lung segments. There were significantly lower numbers of neutrophils and inflammatory cells in the bronchoalveolar lavage of bleomycin-infused lung segments that were treated with pinocembrin. Compared to bleomycin damaged lung segments without drug treatment, pinocembrin administration was associated with significantly lower numbers of immuno-positive CD8+ and CD4+ T cells in the lung parenchyma. Histopathology scoring data showed that pinocembrin treatment was associated with significant improvement in inflammation and overall pathology scores. Hydroxy proline analysis showed that the administration of pinocembrin did not reduce the increased collagen content that was induced by bleomycin in this model. Analyses of Masson’s Trichrome stained sections showed that pinocembrin treatment significantly reduced the connective tissue content in lung segments exposed to bleomycin when compared to bleomycin-infused lungs that did not receive pinocembrin. The striking anti-inflammatory and modest anti-fibrotic remodelling effects of pinocembrin administration were likely linked to the compound’s ability to improve lung pathology and functional compliance in this animal model of pulmonary fibrosis.

Sign in / Sign up

Export Citation Format

Share Document